David Lebowitz
Stock Analyst at Citigroup
(0)
# 3885
Out of 5,243 analysts
102
Total ratings
45.16%
Success rate
-2.43%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
PTC Therapeutics | Maintains: Sell | 26 32 | 42.18 | -24.13% | 3 | Dec 4, 2024 | |
Mirum Pharmaceutical... | Maintains: Strong Buy | 65 68 | 46.49 | 46.27% | 4 | Nov 13, 2024 | |
Incyte | Maintains: Strong Buy | 92 97 | 72.42 | 33.94% | 4 | Oct 30, 2024 | |
Intellia Therapeutic... | Maintains: Neutral | 25 19 | 9.83 | 93.29% | 6 | Oct 25, 2024 | |
Celldex Therapeutics | Initiates Coverage On: Buy | 70 | 22.96 | 204.88% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 13 15 | 8.13 | 84.5% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 178 207 | 133.1 | 55.52% | 12 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 45 44 | 11.63 | 278.33% | 4 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 65 76 | 106.98 | -28.96% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 39 37 | 19.52 | 89.55% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 382 | 272.1 | 40.39% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 42 46 | 35.46 | 29.72% | 2 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 31 | 36.83 | -15.83% | 1 | Dec 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 36 60 | 33.2 | 80.72% | 11 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 103 96 | 62.85 | 52.74% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 18 12 | 2.01 | 497.01% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 170 164 | 252.24 | -34.98% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 36 39 | 13.7 | 184.67% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 21 | 12.87 | 63.17% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 29 27 | 0.63 | 4185.71% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 13 14 | 3.79 | 269.39% | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 324 300 | n/a | n/a | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 10 5 | n/a | n/a | 2 | Aug 10, 2021 |